Title: Ardeparin
Literature References: Low molecular weight heparin prepared by the depolymerization of porcine mucosal heparin in the presence of peroxides. Average mol wt 5500-6500 daltons. Manufacturing process: F. Fussi, US 4281108 (1981 to Hepar Ind.). Description of properties and activity: idem et al., Dev. Biochem. 12, 535 (1981). Clinical pharmacokinetics: S. Troy et al., J. Clin. Pharmacol. 35, 1194 (1995). Clinical trials in prevention of postoperative venous thrombosis: M. N. Levine et al., Arch. Intern. Med. 156, 851 (1996); J. A. Heit et al., Thromb. Haemostasis 77, 32 (1997).
Derivative Type: Sodium salt
Manufacturers' Codes: WY-90493-RD
Trademarks: Normiflo (Wyeth-Ayerst)
Properties: LD50 in mice, rats (mg/kg): >3000, >2000 i.p.; >1000, 354 ±30 i.v.; >6000, >6000 orally (Fussi et al.).
Toxicity data: LD50 in mice, rats (mg/kg): >3000, >2000 i.p.; >1000, 354 ±30 i.v.; >6000, >6000 orally (Fussi et al.)
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.

Others monographs:
FulvoplumierinDeferasiroxDigitoxinNickel Carbonate Hydroxide
PhosvitinAcetyldigitoxinsCuprous Mercuric Iodide4-Nitro-o-phenylenediamine
ParvaquoneDimethylamineCellulose AcetatesRemoxipride
Zirconium SilicateMercumallylic Acid1,6-HexanediamineCeanothic Acid
©2016 DrugLead US FDA&EMEA